Charles River Laboratories

Charles River boosts its clinical and commercial cell therapy manufacturing space in Memphis

08-Nov-2022 By Jane Byrne

Charles River Laboratories International has expanded its cell therapy contract development and manufacturing (CDMO) facility in Tennessee.

Charles River wins gene therapy manufacturing contract from Nanoscope

07-Nov-2022 By Nick Taylor

Charles River Laboratories’ growing gene therapy manufacturing capabilities have landed it a deal with the eye disease biotech Nanoscope Therapeutics.

Charles River opens research facilities in California and Washington

30-Aug-2022 By Jane Byrne

Organization extends turnkey research facility network to San Diego, San Francisco, Thousand Oaks, and Seattle.

Charles River Laboratories becomes first CDMO in North America to receive EMA approval for commercial production of allogenic cell therapy drug product

11-Aug-2022 By Rachel Arthur

Charles River Laboratories, International Inc. has received regulatory approval - in the form of Good Manufacturing Practice (GMP) certification - to commercially produce allogeneic cell therapy drug products for distribution in Europe, from the European...

Charles River to support Belgian firm in manufacturing of saRNA vaccine

23-Jun-2022 By Jane Byrne

Charles River Labs is to manufacture and deliver an early-stage clinical supply of plasmid DNA for drug substance manufacturing to Ziphius Vaccines.

Charles River and ASC Therapeutics expand gene therapy manufacturing agreement

13-Jun-2022 By Rachel Arthur

Charles River Laboratories International and ASC Therapeutics have announced plans to manufacture ASC618, a second-generation gene therapy for hemophilia A.

Charles River closes $380m HemaCare cell therapy takeover

07-Jan-2020 By Nick Taylor

Charles River Laboratories closes $380m takeover of cell therapy specialist HemaCare to expand in fast-growing sector.

Biobetter biotechs emerge as preclinical services clients

16-May-2011 By Nick Taylor

Biotechs set up to take an existing biologic, improve it and license the resulting biobetter are an emerging client for preclinical service providers.